Comparison

Tigecycline

Item no. CS-1876-500mg
Manufacturer ChemScene
Amount 500mg
Category
Type Molecules
Specific against other
ECLASS 10.1 32169090
ECLASS 11.0 32169090
UNSPSC 12000000
Similar products 220620-09-7
Available
Alternative Names
GAR-936
CAS
220620-09-7
Purity
>98%
Formula
C29H39N5O8
MWt
585.65
Solubility
DMSO : 150 mg/mL (256.13 mM; Need ultrasonic)
Clinical Information
Launched
Pathway
Anti-infection; Autophagy
Target
Bacterial; Autophagy
Biological Activity
Tigecycline (GAR-936) is a broad-spectrum glycylcycline antibiotic. The mean inhibitory concentration (MIC) of Tigecycline for E. coli (MG1655 strain) is approximately 125 ng/mL[1]. MIC50 and MIC90 are 1 and 2 mg/L for Acinetobacter baumannii (A. baumannii), respectively[2]. IC50 & Target: Mean MIC: 125 ng/mL (E. coli)[1]
MIC50: 1 mg/mL (A. baumannii)[2]
MIC90: 2 mg/mL (A. baumannii)[2]
In Vitro: Tigecycline (0.63-30 uM, preincubated for 4 days, treated for 72 h) inhibits AML2 cells and HL-60 cells with IC50s of 4.72+/-0.54 and 3.06+/-0.85 uM (freshly prepared). Tigecycline inhibits AML2 cells and HL-60 cells with IC50s of 5.64+/-0.55 and 4.27+/-0.45 uM (1 day preincubation). Tigecycline inhibits AML2 cells and HL-60 cells with IC50s of 5.02+/-0.60 and 4.39+/-0.44 uM (2 day preincubation). Tigecycline inhibits AML2 cells and HL-60 cells with IC50s of 4.09+/-0.41 and 3.95+/-0.39 uM (3 day preincubation). After a 4 day preincubation of Tigecycline in saline, Tigecycline lost its ability to kill TEX human leukemia cells (from IC50ca.5 uM when freshly prepared to IC50>50 uM after 4 days preincubation) as measured by CellTiter Flour assay[1]. In Vivo: Tigecycline (50 mg/kg; intraperitoneal injection; twice a day; for 11 days) reduces tumor volume and weight in NOD/SCID mice[1].
The peak plasma concentration (Cmax), the terminal half-life (t1/2), area under the plasma concentration-time curve (AUC), clearance (CL) and volume of distribution (Vz) are 22.8ug/mL, 108.9 min, 1912.2min*ug/mL, 26.1 mL/min/kg, 4109.4 mL/kg for Tigecycline in saline, respectively. The peak plasma concentration (Cmax), the terminal half-life (t1/2), area under the plasma concentration-time curve (AUC), clearance (CL) and volume of distribution (Vz) are15.7ug/mL, 110.3 min, 2036.5 min*ug/mL, 24.6 mL/min/kg, 3906.2 mL/kg for Tigecycline in formulation (60 mg/mL pyruvate, 3 mg/mL ascorbic acid, pH 7 in saline) , respectively[1].

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 500mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close